We previously reported that after a public meeting held on May 25, 2017, the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Amgen
-
-
The FDA announced yesterday that the Oncologic Drug Advisory Committee (“ODAC”) has scheduled a public meeting to review ABP 215,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. filed a Declaratory Judgment...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]